Back to search

Ireland· IE-PA-PA23266/012/002

Lanreotide Viatris 90 mg solution for injection in a pre-filled syringe

A lanreotide product containing lanreotide, registered in Ireland by Viatris Limited. The same ATC class is registered in 17 of our 19 countries.

ATC H01CB03

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedLanreotide Viatris 90 mg solution for…ATCH01CB03REGISTER NO.IE-PA-PA23266/012/002PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Lanreotide is registered in 17 of 19 countries.

Countries holding a registration under ATC H01CB03 (lanreotide), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 10 of them publish a price we can compare per daily dose

Lanreotide · ATC H01CB03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lanreotide costs, country by country.

Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Lanreotide · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • FR France$53.80
  • CH Switzerland$44.46
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Lanreotide
Manufacturer
Viatris Limited
Country
Ireland (IE)
ATC code
H01CB03
ATC class
Lanreotide
Defined daily dose
3 mg, P
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA23266/012/002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

157 interactions on record for lanreotide.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Lanreotide · interactions on record

157 records

  • 2 severe
  • 151 moderate
  • 4 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • PexidartinibL01EX15severe
  • LiraglutidA08AX02moderate
  • SemaglutidA08AX03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lanreotide in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lanreotide products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

  • Austria · Lanreotid Sun Pharma, Lanreotid Viatris
  • Belgium · Lanreotide Sun, Lanreotide Viatris
  • Cyprus · Somatuline Autogel
  • Czechia · Lanreotid Sun, Lanreotid Zentiva
  • Germany · Lanreotid Sun, Lanreotid Viatris
  • Denmark · Ipstyl Autogel, Lanreotid Amdipharm Limited
  • Estonia · Myrelez, Somatuline Autogel
  • Spain · Lanreotida Sun, Lanreotida Zentiva
  • Finland · Lanreotid Sun, Lanreotid Zentiva
  • France · Lanreotide L.P. Biogaran, Lanréotide Viatris Lp
  • United Kingdom (Northern Ireland) · Lanreotide Mylan, Lanreotide Zentiva
  • Greece · Lanrod, Myrelez
  • Hungary · Lanreotid Sun, Somatuline Autogel
  • Italy · Ipstyl, Lanrenet
  • Lithuania · Myrelez, Somatuline Autogel
  • Luxembourg · Somatuline Autogel Injectable, Somatuline Autogel Injectable120
  • Latvia · Myrelez, Somatuline Autogel
  • Netherlands · Lanreotide Sun, Mytolac
  • Norway · Ipstyl Autogel, Lanreotid Sun
  • Poland · Lanreotide Zentiva, Myrelez
  • Portugal · Myrelez, Somatulina Autogel
  • Romania · Lanreotidă Terapia, Lanreotidă Zentiva
  • Sweden · Lanreotid Amdipharm, Lanreotid Sun
  • Slovenia · Somatuline Autogel
  • Slovakia · Lanreotid Sun, Lanreotid Zentiva

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d1f2c135-e86a-4f9b-98e7-dd97ca3451ef
GET /v1/drugs/d1f2c135-e86a-4f9b-98e7-dd97ca3451ef?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "routes": [
    "Subcutaneous use"
  ],
  "source": "hpra",
  "atc_all": [
    "H01CB03"
  ],
  "strength": null,
  "pa_number": "PA23266/012/002",
  "substances": [
    "Lanreotide"
  ],
  "legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
  "market_info": "Not marketed",
  "authorised_at": "31/01/2025",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about lanreotide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.